两种在研肺炎球菌蛋白疫苗在婴儿中的安全性、反应原性与免疫原性:一项随机II期研究结果
在欧洲开展的多中心、观察者盲法II期试验(NCT01204658)中,婴儿按1:1:1:1随机接受4剂PHiD-CV/dPly/PhtD-10、PHiD-CV/dPly/PhtD-30、PHiD-CV或PCV13,并与DTPa-HBV-IPV/Hib联合接种。两种含dPly和PhtD的PHiD-CV联合疫苗均耐受良好,对dPly和PhtD抗原具有免疫原性,且血清型特异性、蛋白D及联合接种抗原的免疫应答与PHiD-CV组相比未见改变。
要点
- 基础免疫期间未报告与疫苗存在因果关系的>40.0°C发热。
- PHiD-CV/dPly/PhtD-30在基础免疫第3剂后抗Ply和抗PhtD抗体水平优于PHiD-CV/dPly/PhtD-10。
- 两种PHiD-CV/dPly/PhtD组抗Ply和抗PhtD抗体水平均高于对照组,且从基础免疫后至加强免疫后升高。
核心结论
- 两种PHiD-CV/dPly/PhtD制剂与DTPa-HBV-IPV/Hib在婴儿中联合接种均耐受良好,且对dPly和PhtD抗原具有免疫原性。
- 血清型特异性、蛋白D及联合接种抗原的免疫应答与PHiD-CV组相比未见改变。
研究设计与样本
- II期、多中心、观察者盲法试验,在欧洲开展(NCT01204658)。
- 婴儿按1:1:1:1随机接受4剂PHiD-CV/dPly/PhtD-10、PHiD-CV/dPly/PhtD-30、PHiD-CV或13价肺炎球菌结合疫苗(PCV13),与DTPa-HBV-IPV/Hib联合接种,接种年龄约2、3、4和12-15月龄。
- 575名儿童接受基础免疫,564名儿童接受加强免疫。
主要发现
- 非劣效性目标达到;基础免疫期间未报告与疫苗接种存在因果关系的>40.0°C发热。
- 3个PHiD-CV组不良事件发生率看似相似。
- 严重不良事件在PHiD-CV/dPly/PhtD-10、PHiD-CV/dPly/PhtD-30、PHiD-CV和PCV13组分别报告于13、9、21(其中1例与疫苗接种相关)和17名儿童。
- PHiD-CV/dPly/PhtD-30在基础免疫第3剂后抗Ply和抗PhtD抗体水平方面优于PHiD-CV/dPly/PhtD-10。
- 两个PHiD-CV/dPly/PhtD组抗Ply和抗PhtD抗体水平均高于对照组,且从基础免疫后至加强免疫后时间点升高。
关键数值与推荐
- 非劣效性目标:基础免疫后PHiD-CV/dPly/PhtD疫苗组与PHiD-CV组相比>40.0°C发热的发生情况,该目标已达到。
- 剂量优效性:PHiD-CV/dPly/PhtD-30在基础免疫第3剂后抗Ply和抗PhtD抗体水平方面优于PHiD-CV/dPly/PhtD-10。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Vaccination with formulations containing pneumococcal protein antigens such as pneumolysin toxoid (dPly) and histidine-triad protein D (PhtD) may extend serotype-related protection of pneumococcal conjugate vaccines (PCVs) against Streptococcus pneumoniae. METHODS: This phase II, multi-center, observer-blind trial conducted in Europe (NCT01204658) assessed 2 investigational vaccines containing 10 serotype-specific polysaccharide conjugates of PHiD-CV and either 10 or 30µg of dPly and PhtD each. Infants randomized 1:1:1:1 received 4 doses of PHiD-CV/dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, or 13-valent PCV (PCV13), co-administered with DTPa-HBV-IPV/Hib, at ages ∼2, 3, 4 and 12-15months. Occurrences of fever >40.0°C following primary vaccination with PHiD-CV/dPly/PhtD vaccines compared to PHiD-CV (non-inferiority objective), dose superiority, safety and immunogenicity were assessed. RESULTS: 575 children received primary vaccination, and 564 booster vaccination. The non-inferiority objective was met; no fever >40.0°C causally related to vaccination was reported during primary vaccination. Incidence of adverse events appeared similar between the 3 PHiD-CV groups. Serious adverse events were reported in 13, 9, 21 (1 related to vaccination), and 17 children in the PHiD-CV/dPly/PhtD-10, PHiD-CV/dPly/PhtD-30, PHiD-CV, and PCV13 groups, respectively. PHiD-CV/dPly/PhtD-30 was superior to PHiD-CV/dPly/PhtD-10 in terms of post-dose 3 anti-Ply and Anti-PhtD antibody levels. Anti-Ply and anti-PhtD antibody levels were higher in both PHiD-CV/dPly/PhtD groups than in controls and increased from post-primary to post-booster timepoint. Post-primary and booster vaccination, for each PHiD-CV serotype, ≥98.5% of participants in PHiD-CV/dPly/PhtD groups had antibody concentrations ≥ 0.2μg/mL, except for 6B (≥72.3%) and 23F (≥82.7%) post-primary vaccination. Similar results were observed in the PHiD-CV group. Immune responses to protein D and DTPa-HBV-IPV/Hib were within similar ranges for the 3 PHiD-CV groups. CONCLUSION: Both PHiD-CV/dPly/PhtD formulations co-administered with DTPa-HBV-IPV/Hib in infants were well-tolerated and immunogenic for dPly and PhtD antigens, while immune responses to serotype-specific, protein D and co-administered antigens did not appear altered in comparison to PHiD-CV group.
引用
- Prymula R, Szenborn L, Silfverdal SA, et al. Safety, reactogenicity and immunogenicity of two investigational pneumococcal protein-based vaccines: Results from a randomized phase II study in infants. Vaccine. 2017. PMID: 28729019. doi:10.1016/j.vaccine.2017.07.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。